Success Metrics

Clinical Success Rate
85.7%

Based on 30 completed trials

Completion Rate
86%(30/35)
Active Trials
3(7%)
Results Posted
57%(17 trials)
Terminated
5(12%)

Phase Distribution

Ph phase_1
7
16%
Ph phase_4
5
12%
Ph not_applicable
1
2%
Ph phase_2
10
23%
Ph phase_3
15
35%

Phase Distribution

7

Early Stage

10

Mid Stage

20

Late Stage

Phase Distribution38 total trials
Phase 1Safety & dosage
7(18.4%)
Phase 2Efficacy & side effects
10(26.3%)
Phase 3Large-scale testing
15(39.5%)
Phase 4Post-market surveillance
5(13.2%)
N/ANon-phased studies
1(2.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

30 of 36 finished

Non-Completion Rate

16.7%

6 ended early

Currently Active

3

trials recruiting

Total Trials

43

all time

Status Distribution
Active(3)
Completed(30)
Terminated(6)
Other(4)

Detailed Status

Completed30
Terminated5
unknown4
Recruiting2
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
43
Active
3
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (18.4%)
Phase 210 (26.3%)
Phase 315 (39.5%)
Phase 45 (13.2%)
N/A1 (2.6%)

Trials by Status

completed3070%
active_not_recruiting12%
recruiting25%
unknown49%
withdrawn12%
terminated512%

Recent Activity

Clinical Trials (43)

Showing 20 of 43 trialsScroll for more
NCT01892722Phase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Active Not Recruiting
NCT04315948Phase 3

Trial of Treatments for COVID-19 in Hospitalized Adults

Completed
NCT02735707Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
NCT05936229Phase 1

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Withdrawn
NCT06019130Phase 2

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Recruiting
NCT04183491Phase 1

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products

Completed
NCT01412333Phase 3

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Completed
NCT01247324Phase 3

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Completed
NCT05298670Phase 2

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Unknown
NCT03570359Phase 2

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

Completed
NCT04492475Phase 3

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Completed
NCT05024006Not Applicable

Public Health Emergency: SOLIDARITY TRIAL Philippines

Completed
NCT04647669Phase 3

World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments

Unknown
NCT02047734Phase 3

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

Completed
NCT03119701Phase 2

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

Terminated
NCT02294058Phase 3

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Completed
NCT03177083Phase 4

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Completed
NCT04460547

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

Unknown
NCT04343768Phase 2

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Completed
NCT04350671Phase 4

Interferon Beta 1a in Hospitalized COVID-19 Patients

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
43